Table 3.
Reports of changes in circRNA expression in laboratory models and patients with MI.
| Circular RNA | Expression | Target | Mechanism | Model (In vitro, in vivo, human) | Tissue, blood, cell | Reference |
|---|---|---|---|---|---|---|
| Circ-MACF1 | Down | miR-500b-5p | Inhibited apoptosis, improved myocardial function | In vivo, in vitro | Tissue, cardiomyocytes | (201) |
| Circ-SNRK | Down | miR-103-3p | Increased proliferation, reduced apoptosis | In vivo, in vitro | Tissue, cardiomyocytes | (202) |
| Circ-Amotl1 | Down | PDK1, AKT1 | Reduced apoptosis and promoted cardiac repair | In vivo, in vitro, human | Tissue | (203) |
| Circ-0000064 | Down | – | Attenuated autophagy | In vivo | Tissue | (204) |
| Circ-ACR | Down | Pink1 | Repressed autophagy, decreased myocardial infarct sizes | In vitro, in vivo | Tissue, cardiomyocytes | (100) |
| Circ-CDYL | Down | miR-4793-5p | Promoted cell proliferation, improved heart function | In vivo, in vitro | Tissue | (205) |
| Circ-Fndc3b | Down | FUS | Reduced apoptosis, enhanced neovascularization | In vivo, in vitro, human | Tissues, cardiomyocytes | (199) |
| Circ-RCAN2 | Down | – | – | In vivo, in vitro | Tissue | (206) |
| Circ-MICRA | Down | – | – | Human | Blood | (207) |
| Circ-LAS1L | Down | miR-125b | Reduced cell proliferation and migration, induced apoptosis | In vitro, human | Blood, cardiac fibroblasts | (208) |
| Circ-NFIB | Down | miR-433 | Decreased cell proliferation, reduced cardiac fibrosis | In vivo, in vitro | Tissue, cardiac fibroblasts | (209) |
| Circ-PAN3 | Down | miR-421 | Inhibited autophagy, reduced apoptosis | In vivo, in vitro | Tissue, HCMs | (210) |
| Circ-UBXN7 | Down | miR-622 | Decreased apoptosis and inflammation | In vitro, in vivo, | Tissue, H9c2 cells | (211) |
| Circ-C12orf29 | Down | – | – | In vitro, in vivo | Tissue | (206) |
| Circ-JARID2 | Up | miR-9-5p | Inhibited cell viability, promoted apoptosis and inflammatory response | In vitro | H9c2 cells | (212) |
| Circ_0124644 | Up | miR-590-3p | Promoted cardiomyocytes injury via regulating SOX4 | In vitro, human | Blood, AC16 cells | (213) |
| Circ-ROBO2 | Up | miR-1184 | Induced apoptosis | In vivo, in vitro | Tissue | (192) |
| Circ-HIPK3 | Up | miR-93-5p | Inhibited cardiomyocyte proliferation and induced apoptosis | In vivo, in vitro | Tissue, HL-1 cells | (195) |
| Circ-Ttc3 | Up | miR-15b | Decreased ATP depletion and apoptosis | In vivo, in vitro | Tissue, cardiomyocytes | (214) |
| Circ-Arhgap12 | Up | miR-135a-5p | Enhanced apoptosis and oxidative stress | In vivo | Tissue | (215) |
| Circ-ZNF292 | Up | BNIP3 | Increased cell viability, decreased apoptosis and autophagy | In vitro | H9c2 cells | (216) |
| Circ-MAT2B | Up | miR-133 | Induced inflammation | In vitro | H9c2 cells | (197) |
| Circ-Helz | Up | miR-133a-3p | Induced inflammation and pyroptosis, increased myocardial infarct size, decreased cardiac function | In vivo, In vitro | Tissues, cardiomyocytes | (217) |
| Circ-SLC8A1 | Up | miR-133a | - | In vivo, in vitro, human | Tissue, cardiocytes | (218) |
| Circ-FASTKD1 | Up | miR-106a | Reduced the viability, migration, and angiogenesis | In vitro, in vivo | HUVECs, HCMECs | (219) |
| Circ-PAN3 | Up | miR-221 | Increased cell proliferation and migration, induced cardiac fibrosis | In vivo, in vitro | Tissue, cardiac fibroblasts | (220) |
| Circ-000203 | Up | miR-26b-5p | Increased expressions of pro-fibrotic genes | In vitro, in vivo | Tissue | (221) |
| Circ-Ube3a | Up | miR-138-5p | Promoted cell proliferation and migration, aggravated myocardial fibrosis | In vivo, in vitro | M0M-SEVs, M2M-SEVs | (222) |
| Circ-001654, circ-091761, circ-405624, circ-406698 | Up | miR-491-3p, miR-646, miR-603, miR-922 | – | Human | Blood | (223) |
| Circ-0023461 | Up | miR-370-3p | Decreased cell viability, proliferation and migration, increased apoptosis, oxidative stress, and inflammation | In vitro, human | Blood, AC16 cell line | (224) |